Shots
Cross-industry lessons from technology, design thinking, and startups can reshape drug development by encouraging faster iteration, disciplined decision-making, and a stronger focus on real patient needs, unlocking innovations that traditional biotech models may overlook.
Clinical experience and thoughtful engagement with the U.S. Food and Drug Administration highlight the importance of patient insights, transparent…
Shots:
Neurodegenerative care is at a pivotal inflection point, shifting from symptomatic relief to strategies that restore cellular resilience. Blarcamesine (ANAVEX 2-73) advances this upstream approach by activating SIGMAR1 to rebalance autophagy, targeting a core driver of neurodegeneration
Phase IIb/III findings demonstrated a statistically significant slowing of cognitive decline, with the most pronounced benefit seen in patients carrying the…

